Surface Oncology, Inc.</strong> (NASDAQ: <a class="ticker" href="http://finance.yahoo.com/q?s=SURF">SURF</a>) has developed a prosperous pipeline that targets the tumor micro-environment and leverages the innate and adaptive immune system, according to Baird Equity Research. ” data-reactid=”18″ type=”text”>Clinical-stage biopharma Surface Oncology, Inc. (NASDAQ: SURF) has developed a prosperous pipeline that targets the tumor micro-environment and leverages the innate and adaptive immune system, according to Baird Equity Research.
Michael Ulz</a> initiated coverage of Surface Oncology <a href="https://www.benzinga.com/analyst-ratings/upgrades/18/09/12376505/benzingas-top-upgrades-downgrades-for-september-19-2018?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site" rel="nofollow noopener" target="_blank">with an Outperform rating</a> and $23 price target.” data-reactid=”20″ type=”text”>Analyst Michael Ulz initiated coverage of Surface Oncology with an Outperform rating and $23 price target.
here</a>.) ” data-reactid=”22″ type=”text”>In the next few years, Ulz said he anticipates “meaningful upside” stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. This candidate is the most advanced in development and enables macrophages to attack tumor cells, he said. (See the analyst’s track record here.)
“In preclinical studies, SRF231 has demonstrated potent activity both as a monotherapy and in combination with other cancer therapies and is currently in a Phase 1 study, with initial data expected in the first half of 2019. Multiple competitors are targeting CD47, which has provided early clinical target validation.”
The drug has broad utility and a differentiated safety profile, Ulz said. SRF231 should serve as Surface’s value driver, he said.
Novartis AG</strong> (NYSE: <a class="ticker" href="http://finance.yahoo.com/q?s=NVS">NVS</a>) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.” data-reactid=”25″ type=”text”>A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.
“NZV930 (inhibits CD73), partnered with Novartis, is currently in a Phase 1 study, with data expected in the second half of 2019. SRF617 (inhibits CD39) represents a unique opportunity by targeting further upstream in the adenosine pathway and is expected to enter the clinic in late 2019.”
Supplementary pipeline opportunities like IL-27 have demonstrated encouraging activity in preclinical research, while additional programs will target macrophages, T cells and natural killer cells, Ulz said.
“Overall, Surface has built a robust pipeline consisting of seven immunotherapy programs, with two currently in the clinic and four in total expected to be in the clinic by 2020.”
Surface Oncology shares were rallying 9.14 percent to $11.46 at the time of publication Wednesday.
Related Links:</em>” data-reactid=”31″ type=”text”>Related Links:
Regeneron To Make 0M bluebird bio Investment In Cancer Research Collaboration</em>” data-reactid=”32″ type=”text”>Regeneron To Make 0M bluebird bio Investment In Cancer Research Collaboration
The Daily Biotech Pulse: Johnson & Johnson’s Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering</em>” data-reactid=”33″ type=”text”>The Daily Biotech Pulse: Johnson & Johnson’s Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering
Latest Ratings for SURF
|Sep 2018||Baird||Initiates Coverage On||Outperform|
|May 2018||Goldman Sachs||Initiates Coverage On||Neutral|
|May 2018||Cowen & Co.||Initiates Coverage On||Outperform|
View the Latest Analyst Ratings” data-reactid=”37″ type=”text”>View More Analyst Ratings for SURF
View the Latest Analyst Ratings
See more from Benzinga</strong>” data-reactid=”38″ type=”text”>See more from Benzinga
- Guggenheim: Netflix Subscriber Penetration Will Outpace Street Expectations
- With Sale of Agricultural Business Pending, Citi Takes Neutral Stance On Platform Specialty Products
- Gordon Johnson: With 90-95% Conviction Rate, The DoJ’s Tesla Investigation Is ‘Concerning For All Those Long The Stock’
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i>” data-reactid=”43″ type=”text”>© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.